Showing 2521-2530 of 3223 results for "".
- Baxter Launches Digital Image Capture Capability of Panoptic Plus Ophthalmoscopehttps://modernod.com/news/baxter-launches-digital-image-capture-capability-of-panoptic-plus-ophthalmoscope/2481891/Baxter International announced the launch of digital image capture capability for eye exams using its existing Welch Allyn PanOptic Plus Ophthalmoscope. The iExaminer Pro System adds a key technology to routine eye exams, designed to help advance healthcare professio
- Sight Sciences Presents Phase 1 Results of the SAHARA Trial Comparing TearCare to Restasis for the Treatment of Dry Eye Diseasehttps://modernod.com/news/sight-sciences-presents-phase-1-results-of-the-sahara-trial-comparing-tearcare-to-restasis-for-the-treatment-of-dry-eye-disease/2481888/Sight Sciences announced the presentation of the full phase 1 results from the SAHARA randomized controlled trial, demonstrating that interventional eyelid procedures for dry eye disease enabled by TearCare technology were superior at all measured time points to Restasis prescription eye dro
- Johnson & Johnson Vision Presents Data at #Academy23 on ACUVUE MAX 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-vision-presents-data-at-academy23-on-acuvue-max-1-day-contact-lenses/2481885/Johnson & Johnson Vision will present data on the ACUVUE OASYS MAX 1-Day brand family of lenses and research on myopia progression, along with learning opportunities and support of Sight for Kids at the Academy 2023 New Orleans meeting, October 11–14. In celebration
- OKYO Pharma Announces Filing of an IND Application for OK-101 to Treat Neuropathic Corneal Painhttps://modernod.com/news/okyo-pharma-announces-filing-of-an-ind-application-for-ok-101-to-treat-neuropathic-corneal-pain/2481882/OKYO Pharma announced that it filed an investigational new drug (IND) application with the FDA for the development of OK-101 to treat Neuropathic Corneal Pain (NCP). Study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA. There is no FDA-appr
- Harrow Health Changes Corporate Name to Harrow Inc.https://modernod.com/news/harrow-health-changes-corporate-name-to-harrow-inc/2481858/Harrow announced that effective today, it has changed its corporate name from “Harrow Health Inc.” to “Harrow Inc.” to align with the company’s current 5-year strategic plan, which includes an exclusive focus on eye care pharmaceuticals. “Gi
- LKC Technologies Releases Consensus Document for Managing Diabetic Retinopathy in Optometryhttps://modernod.com/news/lkc-technologies-releases-consensus-document-for-managing-diabetic-retinopathy-in-optometry/2481825/LKC Technologies, a provider of functional testing using electroretinography (ERG), released "Modern Fundamentals of Diabetic Retinopathy Management in Optometry," a new report on diabetic retinopathy (DR) developed by an
- Oculis Appoints Rebecca Weil, PhD, as Chief Commercial Officer as it Enters Pre-Commercial Phasehttps://modernod.com/news/oculis-appoints-rebecca-weil-phd-as-chief-commercial-officer-as-it-enters-pre-commercial-phase/2481823/Oculis announced the appointment of Rebecca Weil, PhD, to the role of Chief Commercial Officer. In this role, Ms. Weil will lead the organization to commercial readiness from designing launch strategies for US and globally, and building the required commercial infrastructure to bring all of
- BVI Expands its Presence in Spain and Portugal Acquiring Medical Mixhttps://modernod.com/news/bvi-expands-its-presence-in-spain-and-portugal-acquiring-medical-mix/2481813/BVI announced it has acquired Medical Mix, an ophthalmic medical device supplier in Spain and Portugal. Financial terms of the deal were not disclosed. BVI said its European footprint with direct sales representatives and infrastructure now spans all major western Eu
- CooperVision to Spotlight Myopia Control and Management Advocacy at ESCRShttps://modernod.com/news/coopervision-to-spotlight-myopia-control-and-management-advocacy-at-escrs/2481809/CooperVision will spotlight advancing myopia control and management as standard of care across all ocular health sectors at the 2023 European Society of Cataract and Refractive Surgeons (ESCRS) conference in Vienna. On September 7, a thought leadership panel will be held
- Rayner Unveils Enhancements to Digital Platforms at ESCRS 2023https://modernod.com/news/rayner-unveils-enhancements-to-digital-platforms-at-escrs-2023/2481808/Rayner has announced a series of updates to its digital platforms, RayPRO and Peer2Peer, designed to redefine patient-reported outcome measures (PROMs) and elevate clinical ophthalmic education. Attendees of the ESCRS 2023 congress are invited to explore these advancements at Booth B303